Allogeneic transplantation after failure of chimeric antigen receptor‐T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70010 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Angelica Barone und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NextGenerationEU, Fondazione IRCCS Istituto Nazionale dei Tumori, Associazione Italiana contro le Leucemie-linfomi e mieloma (AIL) Milano.
Abstract (Originalsprache)
Clinical outcome after chimeric antigen receptor (CAR)‐T‐cell failure in large B‐cell lymphoma (LBCL) is dismal. Allogeneic stem cell transplantation (alloSCT) represents a potentially curative salvage for relapsed/refractory LBCL, although concerns remain regarding its feasibility and safety in patients exposed to CAR‐T and bispecific antibodies. Between 2019 and 2025, 83 disease progressions were documented among 170 LBCL patients treated with CAR‐T in two academic centres; 69 (83%) started salvage treatment, the most frequent being glofitamab in 38 (55%); among those, we retrospectively analysed outcomes of 35 candidates for alloSCT consolidation. Ultimately, 13 (37%) underwent alloSCT after achieving complete (CR) or partial response. The median number of previous therapies was 5. All patients engrafted; grade III–IV acute graft‐versus‐host disease (GvHD) occurred in 8% and moderate‐to‐severe chronic GvHD in 15% of patients respectively. At 18.4‐month median follow‐up, non‐relapse mortality was 0%; all allografted patients are alive in CR; conversely, the outcome of 22 patients not proceeding to transplant was poor, with a median overall survival of 11.7 months and 13 disease‐related deaths (59%). Although in a small cohort of patients, our data highlight the potential benefit of alloSCT consolidation in selected responders to salvage regimens despite the extensive prior treatments with T‐cell redirecting therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Milan, Milan, Italy.
- Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
ORCID-Profile: Angelica Barone, Federico Stella, Carmelo Carlo-Stella, Paolo Corradini
Förderung
- NextGenerationEU
- Fondazione IRCCS Istituto Nazionale dei Tumori
- Associazione Italiana contro le Leucemie-linfomi e mieloma (AIL) Milano
- Società Italiana di Ematologia
- Società Italiana di Ematologia Sperimentale
Zitieren
APA
Barone, A., De Philippis, C., Stella, F., Dodero, A., Sarina, B., Pennisi, M., Santoro, A., Carlo-Stella, C., Guidetti, A., Bramanti, S., & Corradini, P. (2025). Allogeneic transplantation after failure of chimeric antigen receptor‐T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes. British Journal of Haematology. https://doi.org/10.1111/bjh.70010
Vancouver
Barone A, De Philippis C, Stella F, Dodero A, Sarina B, Pennisi M, et al. Allogeneic transplantation after failure of chimeric antigen receptor‐T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes. British Journal of Haematology. 2025. doi:10.1111/bjh.70010
BibTeX
@article{Barone2025,
author = {Barone, Angelica and De Philippis, Chiara and Stella, Federico and Dodero, Anna and Sarina, Barbara and Pennisi, Martina and Santoro, Armando and Carlo-Stella, Carmelo and Guidetti, Anna and Bramanti, Stefania and Corradini, Paolo},
title = {Allogeneic transplantation after failure of chimeric antigen receptor‐T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70010}
}
EUVIMED